|Bid||1.885 x 0|
|Ask||1.895 x 0|
|Day's range||1.870 - 1.905|
|52-week range||1.227 - 1.945|
|PE ratio (TTM)||19.54|
|Earnings date||18 Oct. 2018|
|Forward dividend & yield||0.07 (3.70%)|
|1y target est||1.76|
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Australian Pharmaceutical Industries Limited (ASX:API) due to its excellent fundamentals inRead More...
Should you sell Sigma Healthcare Ltd (ASX:SIG) shares after its weak half year result and outlook?
Two important questions to ask before you buy Australian Pharmaceutical Industries Limited (ASX:API) is, how it makes money and how it spends its cash. What is left after investment, determinesRead More...
Australian Pharmaceutical Industries Limited (ASX:API), a healthcare company based in Australia, saw significant share price volatility over the past couple of months on the ASX, rising to the highs ofRead More...
While small-cap stocks, such as Australian Pharmaceutical Industries Limited (ASX:API) with its market cap of AU$647.54M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
Australian Pharmaceutical Industries, Folkestone Education Trust, and InvoCare have one big thing in common. They are on my list of the best dividend stocks which have generously contributed to myRead More...
Australian Pharmaceutical Industries, the owner of Priceline stores, is seeking acquisitions to boost its retail network.
Challenging consumer sentiment and more competition have hit Australian Pharmaceutical Industries's half-year profit, but the company will continue to expand.
Challenging consumer sentiment and greater competition have crimped the half-year profit of Australian Pharamaceutical Industries.